Advanced oxidation protein products in serum of patients with myotonic disease type 1: Association with serum γ-glutamyltransferase and disease severity

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 7, 2005, Pages 745-747

  Siciliano, Gabriele ^a   Pasquali, Livia ^a   Rocchi, Anna ^a   Falorni, Michela ^a   Galluzzi, Fabio ^a   Rocco, Angela ^a   Malvaldi, Gino ^a   Pompella, Alfonso ^a   Paolicchi, Aldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

glutamyltransferase; Myotonic dystrophy; Oxidative stress

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CATARACT; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEART DISEASE; HUMAN; MALE; MUSCLE DISEASE; MYOTONIC DYSTROPHY; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 26844531229     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2005.127     Document Type: Article

References (23)

1. Shaw DJ, Harper PS. Myotonic dystrophy: developments in molecular genetics. Br Med Bull 1989;45:745-59.
2. Harper PS, editor. Myotonic dystrophy. Major series in neurology. London: WB Saunders, 1989.
3. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of trinucleotide (CTG) repeat at 3′ end of a transcription encoding a protein kinase family member. Cell 1992;68:799-808.
4. Fu YH, Pizzuti A, Fenwick RG Jr, King JR, Rajnarayan S, Dunne PW, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992; 255;1256-8.
5. Usuki F, Ishiura S. Expanded CTG repeats in myotonin protein kinase increase susceptibility to oxidative stress. NeuroReport 1998;9:2291-6.
6. Ihara Y, Mori A, Hayabara T, Namba R, Nobukuni K, Sato K, et al. Free radicals, lipid peroxides and antioxidants in blood of patients with myotonic dystrophy. J Neurol 1995;242:119-22.
7. Ono S, Kurisaki H, Inouye K, Mannen T. Ragged-red fibers in myotonic dystrophy. J Neurol Sci 1986; 74:247-55.
8. Sahashi K, Tanaka M, Tashiro M, Ohno K, Ibi T, Takahashi A, et al. Increased mitochondrial DNA deletions in the skeletal muscle of myotonic dystrophy. Gerontology 1992;38:18-29.
9. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta 1995;1271:281-6.
10. Siciliano G, Mancuso M, Tedeschi D, Manca ML, Renna MR, Lombardi V, et al. Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain Res Bull 2001;56:405-10.
11. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51:597-604.
12. Paolicchi A, Dominici S, Pieri L, Maellaro E, Pompella A. Glutathione catabolism as a signaling mechanism. Biochem Pharmacol 2002;64:1027-35.
13. Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 2003;66:1499-503.
14. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004;38:535-9.
15. Gennarelli M, Pavoni M, Amicucci P, Novelli G, Dallapiccola B. A single polymerase chain reaction-based protocol for detecting normal and expanded alleles in myotonic dystrophy. Diagn Mol Pathol 1998;7:135-7.
16. Gennarelli M, Novelli G, Andreasi Bassi F, Martorell L, Cornet M, Menegazzo E, et al. Prediction of myotonic dystrophy clinical severity based on the number of intragenic [CTG]n trinucleotide repeats. Am J Med Genet 1996;65:342-7.
17. Mathieu J, De Braekeleer M, Prevost C, Boily C. Myotonic dystrophy: clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation. Neurology 1992;42:203-8.
18. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.
19. Huseby NE, Stromme JH. Practical points regarding routine determination of gamma-glutamyl transferase (gamma-GT) in serum with a kinetic method at 37°C. Scand J Clin Lab Invest 1974;34:357-63.
20. Ronnemaa T, Alaranta H, Viikari J, Tilvis R, Falck B. Increased activity of serum gamma-glutamyl-transferase in myotonic dystrophy. Acta Med Scand 1987;222: 267-73.
21. Huseby NE. Multiple forms of serum gamma-glutamyltransferase. Association of the enzyme with lipoproteins. Clin Chim Acta 1982;124:103-12.
22. Schiele F, Guilmin AM, Detienne H, Siest G. Gamma-glutamyltransferase activity in plasma: statistical distributions, individual variations, and reference intervals. Clin Chem 1997;23:1023-8.
23. Tapscott SJ. Deconstructing myotonic dystrophy. Science 2000;289:1701-2.